Predicting CNS Relapse in Diffuse Large B-Cell Lymphoma

A six-factor model identifies high-risk patients who should be considered for central nervous system prophylaxis.

Leptomeningeal or parenchymal brain relapse is a feared complication in patients with diffuse large B-cell lymphoma (DLBCL). But identifying those most at risk and the approach to central nervous system (CNS) prophylaxis remain controversial.

Now, investigators have developed a CNS risk-assessment model for DLBCL patients by analyzing clinical factors among a large cohort treated in German multicenter clinical trials. The researchers then validated the model in a British Columbia population-based cohort. Patients in the development cohort were HIV-negative and received R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) or a CHOP-like regimen; some with known risk-factors for CNS involvement (such as known CNS dise…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Predicting CNS Relapse in Diffuse Large B-Cell Lymphoma

Topics

Reviewing Author